Coherus BioSciences Inc. Daily Stock Analysis

Daily Stock Analysis, CHRS, Coherus BioSciences Inc, priceseries

Coherus BioSciences Inc. Daily Stock Analysis
Stock Information
Open
11.49
Close
11.61
High
11.85
Low
11.30
Previous Close
11.85
Daily Price Gain
-0.24
YTD High
16.48
YTD High Date
Jan 4, 2022
YTD Low
10.53
YTD Low Date
Feb 24, 2022
YTD Price Change
-4.80
YTD Gain
-29.25%
52 Week High
19.32
52 Week High Date
Nov 16, 2021
52 Week Low
10.53
52 Week Low Date
Feb 24, 2022
52 Week Price Change
-4.37
52 Week Gain
-27.35%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 27. 2017
22.90
Mar 8. 2017
24.15
7 Trading Days
5.47%
Link
LONG
Jan 2. 2018
9.55
Jan 17. 2018
12.23
10 Trading Days
28.01%
Link
LONG
May 1. 2018
12.15
May 18. 2018
15.62
13 Trading Days
28.56%
Link
LONG
Jan 7. 2019
10.25
Jan 17. 2019
11.31
8 Trading Days
10.31%
Link
LONG
Jan 29. 2019
12.69
Feb 11. 2019
13.81
9 Trading Days
8.80%
Link
LONG
May 15. 2019
17.19
May 31. 2019
18.82
11 Trading Days
9.47%
Link
LONG
Jun 14. 2019
18.65
Jul 8. 2019
21.67
15 Trading Days
16.21%
Link
LONG
Aug 19. 2019
19.71
Sep 4. 2019
21.12
11 Trading Days
7.13%
Link
LONG
Feb 6. 2020
19.44
Feb 24. 2020
21.21
11 Trading Days
9.09%
Link
LONG
Aug 13. 2021
13.93
Sep 7. 2021
15.42
16 Trading Days
10.68%
Link
LONG
Sep 16. 2021
16.03
Sep 28. 2021
17.12
8 Trading Days
6.80%
Link
Company Information
Stock Symbol
CHRS
Exchange
NasdaqGM
Company URL
http://www.coherus.com
Company Phone
(650) 649-3530
CEO
Denny M. Lanfear
Headquarters
California
Business Address
C/O DENNIS M. LANFEAR, 333 TWIN DOLPHIN DR, SUITE 600, REDWOOD CITY, CA 94065
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001512762
About

Coherus BioSciences, Inc. is a late-stage clinical biologics platform company, which engages in the development and commercializition of biosimilar therapeutics worldwide. It focuses on global biosimilar market. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar, and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

Description

Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company's product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, nonsmall cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behcet's Disease, Crohn's Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular (wet) age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Coherus Biosciences, Inc. has license agreement with Daiichi Sankyo Company, Limited; Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH; Genentech, Inc.; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading